25CN-NBOH

25CN-NBOH is a psychedelic drug that is part of the 2C family. It is known for its hallucinogenic effects, which are similar to those of LSD and psilocybin.

History

25CN-NBOH was first synthesized by a team at the University of Copenhagen in Denmark. It was developed as a potential tool for use in neuroscience research, specifically for studying the 5-HT2A receptor, which is thought to be the primary target of psychedelic drugs.

Pharmacology

25CN-NBOH is a partial agonist at the 5-HT2A receptor. This means that it binds to this receptor and activates it, but not to the same extent as a full agonist would. The drug's hallucinogenic effects are thought to be primarily due to this action.

Effects

The effects of 25CN-NBOH can vary greatly depending on the dose taken, the individual's physiology, and the setting in which the drug is used. Common effects include visual hallucinations, altered thought processes, and a heightened sense of empathy or emotional connectedness. Some users also report experiencing synesthesia, a phenomenon in which one type of sensory input (such as sound) is perceived as another (such as color).

Legal status

The legal status of 25CN-NBOH varies by country. In some places, it is completely illegal, while in others it is controlled or regulated to some extent. In the United States, it is classified as a Schedule I drug under the Controlled Substances Act, meaning it is illegal to manufacture, distribute, or possess without a license.

See also

• 2C-B
• 25I-NBOMe
• Psychedelic drug
• Hallucinogen

25CN-NBOH Resources
Latest articles Most recent articles Ongoing trials	Wikipedia